ABBV-400 Clinical Trials (2026): 3 Studies for Advanced Solid Tumors & Biliary Tract Cancers
Hipa.ai Research · Source: ClinicalTrials.gov / AACT
Synced daily from ClinicalTrials.gov via AACT. Last sync: .
3 ABBV-400 clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 3 indications (including Advanced Solid Tumors & Biliary Tract Cancers) and 1,125 total planned enrollment. 1 ABBV-400 clinical trial is actively recruiting at 1 U.S. site across 1 state. Most recent activity: NCT05029882 (Nov 2027).
Where to Participate: All ABBV-400 Trial Sites in the U.S. (1 site across 1 state)
Every actively recruiting ABBV-400trial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.
| State | Facility | City | Trial | Map |
|---|---|---|---|---|
| TX | START-San Antonio | San Antonio78229 | NCT06084481 | Map |
ABBV-400 clinical trials at a glance: phase × recruitment status
| Phase | recruiting | active not recruiting | Total |
|---|---|---|---|
| P1 | 1 | 1 | 2 |
| P2 | 1 | 1 |
Recruiting ABBV-400 clinical trials (1)
Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).
| NCT ID | Title | Phase | Indication | Enrollment | Started |
|---|---|---|---|---|---|
| NCT06084481 | IVStudy to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | P1 | Hepatocellular Carcinoma | 325 | Nov 2023 |
ABBV-400 clinical trials by indication
Unresectable Metastatic Colorectal Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06107413 | IV | P2 | active not recruiting | Study to Assess Adverse Events and Change in Disease Activity in Previously Treated Adult Participants Receiving Intravenous (IV) ABBV-400 With Unresectable Metastatic Colorectal Cancer in Combination With IV Fluorouracil, Folinic Acid, and Bevacizumab |
Hepatocellular Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06084481 | IV | P1 | recruiting | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 |
Non-Small Cell Lung Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05029882 | IV | P1 | active not recruiting | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 as Monotherapy and in Combination With IV Bevacizumab |
ABBV-400 pivotal trial highlights (Phase 2/3/4)
Phase-2/3/4 studies with named acronyms — the registration-grade trials most cited in label discussions and Wikipedia.
| Acronym | NCT | Phase | Status | Indication | Enrollment | PubMed |
|---|---|---|---|---|---|---|
| IV | NCT06107413 | P2 | active not recruiting | Unresectable Metastatic Colorectal Cancer | 280 | — |
All ABBV-400 trials (3)
Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.
| NCT ID | Acronym | Title | Phase | Status | Enrollment | Sponsor | Started |
|---|---|---|---|---|---|---|---|
| NCT05029882 | IV | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 as Monotherapy and in Combination With IV Bevacizumab | P1 | active not recruiting | 520 | AbbVie | Oct 2021 |
| NCT06084481 | IV | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | P1 | recruiting | 325 | AbbVie | Nov 2023 |
| NCT06107413 | IV | Study to Assess Adverse Events and Change in Disease Activity in Previously Treated Adult Participants Receiving Intravenous (IV) ABBV-400 With Unresectable Metastatic Colorectal Cancer in Combination With IV Fluorouracil, Folinic Acid, and Bevacizumab | P2 | active not recruiting | 280 | AbbVie | Nov 2023 |
ABBV-400 clinical trials: frequently asked questions
- How many ABBV-400 clinical trials are there?
- 3 ABBV-400 clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 1 is actively recruiting participants.
- Are ABBV-400 clinical trials recruiting in 2026?
- Yes — 1 ABBV-400 trial is actively recruiting in 2026, with 1 U.S. site across 1 state. See the recruiting trials and the per-state site list further down this page.
- What conditions is ABBV-400 being studied for?
- ABBV-400 is being studied for Advanced Solid Tumors, Biliary Tract Cancers, Colorectal Cancer, Esophageal Squamous Cell Carcinoma, Gastroesophageal Adenocarcinoma and 8 more. The trials are grouped by indication on this page.
- What phase is ABBV-400 in?
- ABBV-400 clinical trials span 1 Phase 2, 2 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
- Who sponsors ABBV-400 clinical trials?
- The lead sponsor across the most ABBV-400 trials is AbbVie. Each trial row links to the full study detail page including sponsor information.
Sources and methodology
Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming ABBV-400as an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.
Last refreshed .
Related pages on Hipa.ai: